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The sensory nervous and immune systems, historically considered autonomous, actually 
work in concert to promote host defense and tissue homeostasis. These systems interact 
with each other through a common language of cell surface G protein-coupled receptors 
and receptor tyrosine kinases as well as cytokines, growth factors, and neuropeptides. 
While this bidirectional communication is adaptive in many settings, helping protect from 
danger, it can also become maladaptive and contribute to disease pathophysiology. 
The fundamental logic of how, where, and when sensory neurons and immune cells 
contribute to either health or disease remains, however, unclear. Our lab and others’ 
have begun to explore how this neuro-immune reciprocal dialog contributes to phys-
iological and pathological immune responses and sensory disorders. The cumulative 
results collected so far indicate that there is an important role for nociceptors (noxious 
stimulus detecting sensory neurons) in driving immune responses, but that this is highly 
context dependent. To illustrate this concept, we present our findings in a model of 
airway inflammation, in which nociceptors seem to have major involvement in type 2 but 
not type 1 adaptive immunity.
Keywords: allergy and immunology, sensory neurons, asthma, inflammation, neuro-immunological signaling
iNFLAMMATiON iS A NeRvOUS THiNG
Inflammation was first characterized by Celsus as having four cardinal signs, dolor (pain), calor 
(heat), rubor (redness), and tumor (swelling) (1). Although we typically think of inflammation as 
an immune-mediated phenomenon, each of these characteristics is essentially due to neuronal 
activation. The local depolarization produced by the direct activation of membrane transducers in 
the peripheral terminals of nociceptors by noxious stimuli initiates action potentials which travel 
orthodromically from the periphery to the central nervous system to initiate reflexes (withdrawal, 
scratching, cough) and sensations (pain, itch) (2, 3). However, when the action potentials reach 
branch points of the sensory neurons they are also transmitted antidromically back to the peripheral 
terminals in a process known as the axon reflex (4, 5). The local depolarization and the action reflex 
are the means by which neurogenic inflammation is initiated. Calcium influx through voltage-gated 
calcium channels triggers the rapid and local release of neurotransmitters from activated peripheral 
terminals or those invaded by antidromic action potentials (4, 5). Neuropeptides, such as calcitonin 
gene-related peptide (CGRP) and substance P (SP), act on endothelial and smooth muscle cells to 
produce redness and heat (secondary to vasodilation) and neurogenic edema (secondary to plasma 
extravasation due to increased capillary permeability) (6, 7). This neurogenic component of the 
response to acute injury has long been recognized. However, the sensory neuronal involvement goes 
beyond contributing just to the vascular component of the inflammatory response to infection or 
injury. Complex reciprocal interactions between the sensory nervous and the immune systems have 
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recently been detected that drive both inflammatory pain hyper-
sensitivity and immune cell recruitment and activation (2, 8).
An early indication that nociceptors play a major role in 
autoimmunity was the observation that denervation of a limb fol-
lowing a nerve injury prevented the subsequent development of 
arthritis in that limb (9). This clinical finding can be recapitulated 
in rodents, where eliminating sensory fiber innervation decreases 
inflammation in models of rheumatoid arthritis (10). Although 
denervation can protect from arthritis, blocking nerve activity 
can worsen experimental inflammation, as observed in a serum-
transfer model of arthritis (11). These findings seem contrary, 
but may indicate that nociceptors play distinct roles during dif-
ferent phases of the immune response in arthritis; perhaps they 
are required for initiation of disease, but limit arthritic effector 
responses (mimicked in the serum-transfer model). During 
initiation of immune responses, the peptides produced by and 
released from the peripheral terminals of sensory neurons can 
direct the differentiation of lymphocytes (8, 12–18) and promote 
the recruitment of immune cells, and therefore may determine 
the localization, extent, duration, and type of inflammation taking 
place. In consequence, this neuro-immune interaction may result 
in a broad spectrum of different pathophysiological changes and 
disease states. Understanding the specifics of the interactions 
between sensory neurons and immune cells and defining the rules 
under which they operate will open new avenues for understand-
ing immunity and for developing novel therapeutic strategies (2). 
In this perspective, we highlight context-dependent aspects of 
neuro-immune interactions involving sensory neurons.
PHYSiOLOGiCAL BASiS FOR CONTeXT-
DePeNDeNT NeURO-iMMUNe 
COMMUNiCATiON
The primary goal of the immune system is to sense pathogens and 
respond accordingly for their effective removal, while limiting tis-
sue damage and deleterious autoimmunity (19). To mount these 
responses, the immune system relies on an arsenal of immune cell 
subtypes specifically programed to eradicate a myriad of distinct 
pathogens. For example, different subpopulations of effector 
cells arise during activation of mature naïve CD4+ T  cells by 
innate cells responding to distinct environmental cues, yielding 
highly adaptable responses to the type of pathogen. Although 
they lack somatically re-arranged antigen receptors, different 
innate lymphoid cell (ILC) lineages also contribute to differential 
pathogen responses (20). Historically, immune responses have 
been classified into three distinct groups classified by the type of 
T helper cell induced: type 1 responses, which provide protection 
against intracellular microbes through, in part, the activation of 
phagocytes (21); type 2 responses, which defend against parasites 
such as helminths (also triggered by allergens, venoms, and 
toxins) (22); and type 3 responses that protect against extracel-
lular pathogens (including yeasts/fungi) (23). Type 1 immunity 
is characterized by T-bet+ IFNγ-producing ILC1, CD8+ cytotoxic 
T  cells, and CD4+ Th1  cells which defend against intracellular 
virus and microbes through activation of CD8+ cytotoxic T cells. 
Type 2 immunity is defined by GATA-3+ ILC2, and Th2 cells that 
produce IL-4, IL-5, and IL-13, which induce mast cell, basophil, 
and eosinophil activation, as well as IgE antibody production 
(24). Type 3 immunity is mediated by ILC3s, and Th17 cells that 
produce IL-17, IL-22 (25), or both, which activate mononuclear 
phagocytes but also recruit neutrophils and induce epithelial 
antimicrobial responses.
For each of these different types of immunity, there are several 
stereotypical components. First, the insult must be “sensed.” In 
the immune system, pattern recognition receptors (PRRs) have 
evolved to respond to a diverse array of stimuli (26). PRRs include 
TLRs, C-type lectin-like receptors, and NOD-like receptors, 
which are expressed on the surface and in intracellular compart-
ments of a variety of cell types, including dendritic cells (DCs) 
and epithelial cells. Triggering PRRs activates DCs, which then 
stimulate antigen-specific T  cells and tune the type of Th cell 
response required (i.e., type 1, 2, or 3). Indirect activation of DCs 
can also occur, for example, via epithelial cell-derived factors, 
such as thymic stromal lymphopoietin (TSLP), which perhaps 
conditions DCs to induce Th2 cell responses (27). Triggering 
type 2 immunity may also involve DC PRRs, enzymatic activity 
of allergens with intrinsic protease activity, recognition of tissue 
damage, or distinct metabolic changes caused by allergens or 
helminths (22).
Next, information must travel to peripheral immune tissues, 
such as spleen and lymph nodes, where it is transmitted to mana-
gerial cells—mostly T helper cells, which are instructed by innate 
immune cells to differentiate into effector populations. Typically, 
primed DCs, in addition to presenting antigen in the context of 
costimulatory molecules to naïve T cells (Th0), will also instruct 
naive T cells to differentiate into an appropriate effector type (Th1, 
Th2, Th17, and Treg) by releasing type-specific cytokines (22). 
For example, in a type 1 bacterial infection, DC make IL-12, IL-6, 
and IL-1β which drive Th1 cell differentiation (21); (b) while in 
a type 17 infection, TGF-β, IL-6, and IL-23 enhance ROR-γt and 
STAT3 activity and drive Th17 differentiation (23); (c) in type 2 
inflammation, IL-4 from DCs, epithelial cells, basophils, CD4+ 
Th2 cells, or ILC2 cells stimulates GATA-3 and STAT5, STAT6 
to promote Th2 differentiation (22, 28, 29). Once polarized, the 
effector T cells travel back to the original location of the insult 
to direct appropriate host defense responses. They do so via 
the release of an “effector” sets of cytokines, such as IFN-γ by 
Th1 cells; IL-17, IL-21, and IL-22 by Th17 cells; and IL-4, IL-5, 
IL-9, and IL-13 by pro-inflammatory Th2 cells (24, 30). In disease 
states, these physiological responses are subverted to pathology. 
Each inflammatory disease is generally dominated by one par-
ticular type of immunity, which depends on the initial trigger 
and the individual’s micro- and macroenvironment and genetic 
susceptibilities. For example, types 1 and 3 immunities mediate 
autoimmune diseases (rheumatoid arthritis and ulcerative colitis), 
whereas type 2 responses cause allergies (asthma and eczema).
wHeRe DO NeURONS FiT iNTO THiS 
MODeL?
The somatosensory nervous system is positioned anatomically 
to be able to directly modulate immunity in secondary and 
primary lymphoid tissues, skin, and mucosa, by interacting with 
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immune cells in locations where they are stationed to monitor 
for disturbances in barrier function and homeostasis (31–34). 
There is also crosstalk between the sensory neurons and the epi-
thelial barrier (35), another important determinant of immune 
responses (36). In addition, sensory neurons express a wide array 
of ion channel receptors specialized for detecting danger signals. 
These danger signals can include excess heat or cold (TRPV1, 
TRPM8), chemical (TRPA1), and mechanical (Piezo2) insults 
(2, 5, 37). They can also sense protons (TRPV1) and the ATP 
released upon tissue damage and apoptosis (P2X3R). After neu-
rons sense environmental cues, the acute sensory input travels 
to the CNS, prompting withdrawal and defensive reflexes (fever, 
cough, scratch, and vomiting) (2, 38–41).
Neuronal activation by the immune system has been fairly 
well studied. Nociceptors are activated by cytokines: IL-1β (42) 
or CCL3 (43) in the context of pain, IL-5 during allergic airway 
inflammation (8), IL-31 during lymphoma-associated itch (44), 
TSLP and IL-4 during atopic dermatitis (35), IL-33 after contact 
with poison ivy (45), and IL-23 during psoriasis (46). While 
TNF-α leads to the activation of nuclear factor κB (NF-κB) (47), 
MAP, and tyrosine kinases are typically downstream of IL-1R in 
sensory neurons (42). These kinases, including p38 (48), JAK1 
(49, 50), and the transcription factor STAT3 (51), are just some 
of the downstream signaling molecules that lead to ion channel 
sensitization, a state of heightened activity. Much of nociceptor 
sensitization is related to a decrease in the activation threshold of 
TRPV1 or TRPA1 (52, 53), and of the sodium channels Nav1.7, 
Nav1.8, and Nav1.9 (54, 55), lowering nociceptor activation 
threshold results in pain hypersensitivity and increased itch, but 
also greater local release of neuropeptides that in turn activate 
immune cells to release more cytokines (2). Overall, inflamma-
tion leads to the simultaneous release of many pain sensitizing 
mediators. As a consequence, pharmacologically targeting 
only one of these agents may have limited effects. In addition, 
there is a negative feedback loop: IL-1β and IL-4 may, via the 
JAK–STAT axis, trigger increased expression of opioid receptors 
in neurons and, therefore, sub-acutely have anti-nociceptive and 
anti-inflammatory effects (56, 57).
PATHOGeN DeFeNSe
We increasingly recognize that nociceptors play a much broader 
role in sensing their environment than originally thought; they 
can also directly detect bacteria and fungi, as well as may prod-
ucts of the immune response, including cytokines, chemokines, 
and immunoglobulins (2, 5, 37). Nociceptors express a variety 
of PRRs that directly recognize bacteria (58) and fungi (59, 60). 
Staphylococcus aureus is able to activate nociceptors through a 
twofold mechanism: (a) secreted pore forming toxins, for exam-
ple, α-hemolysin, which permeabilizes the nociceptors’ cell mem-
brane allowing influx of extracellular cations and (b) N-formylated 
peptides that are membrane-bound peptides that activate their 
cognate receptors (formyl peptide receptors) on the surface of 
nociceptors (58). Following experimental ablation of these neu-
rons, the pain associated with bacterial infection is, as expected, 
decreased, but surprisingly local immune infiltration is increased. 
These data suggest that bacteria may have evolved the capacity to 
activate and co-opt nociceptor function to dampen innate immune 
responses and facilitate their survival (58). However, the neuronal 
response may be distinct for different types of pathogens. In the 
context of Escherichia coli peritonitis infection, transection of the 
vagus nerve decreased ILC3 cell numbers, reduced pro-resolving 
mediator levels, and altered peritoneal macrophage numbers. 
Exogenous acetylcholine or pro-resolving mediators restored tis-
sue resolution tone and host responses to E. coli infections (61). 
In intestinal organ cultures, capsaicin-sensitive enteric nervous 
system neurons seem to distinguish among different bacterial 
infections (62). For example, despite belonging to the same 
Clostridium bacterial subset, only a few nociceptors respond to 
P. magnus, while up to 60% of the capsaicin responsive nociceptors 
showed calcium flux when exposed to C. Ramosum. Interestingly, 
P. magnus downregulates genes encoding for SP, Secretogranin 
III, and galanin while it upregulates neurotensin and angiotensin. 
Intriguingly, C. Ramosum had the opposite effect (62). This seems 
to indicate that nociceptors may be able to change their activation 
depending on the type of immune response elicited by commen-
sal vs pathogen and contribute in this way to either regulatory or 
type1/17 immunity.
Beyond their sensory role, neurons also promote host defense 
and do this in part by direct interaction with immune cells. The 
activation of sensory neurons results in the secretion of neuro-
peptides from their peripheral terminals that cause the recruit-
ment, activation, and influx of immune cells (37, 63–66). CGRP 
and VIP can bias DCs to produce type Th1, Th2, or Th17-skewing 
cytokines and enhance DCs migration to the lymph nodes 
(67, 68). The same neuropeptide can have multiple different 
effects, in some cases biasing to Th1, Th2, or serving a regulatory 
role (13, 67). Along with SP, these neuropeptides can also act on 
Langerhans (63), Th2 (68, 69), and ILC2 cells (8, 16) to change 
their activation states in the skin during models of contact hyper-
sensitivity or psoriasis, and in allergic airway disease models (8). 
For example, in Th2-immunity, SP released by itch transducing 
neurons is sensed by mast cells which degranulate and release 
secondary mediators such as histamine, causing swelling and 
further enhancing the neurogenic response (3, 18, 70). Skin is 
innervated both by sympathetic efferent and nociceptor affer-
ent neurons, but the denervation produced by the ablation of 
nociceptors alone is sufficient to reduce contact sensitivity 
inflammatory responses (71). Brian Kim’s group has studied the 
contribution of sensory neurons in AD-like skin inflammation 
induced by the topical irritant MC903 (calcipotriol) (50). They 
found that while the type 2 cytokines IL-4 and IL-13 directly 
activate (calcium flux) both mouse and human sensory neurons, 
they did not elicit acute itch. IL-4 sensitized subsets of neurons 
to respond to previously sub-threshold pruritogen levels (such 
as histamine), significantly increasing scratching. They hypoth-
esized that, rather than acute itch, neuronal type 2 cytokine 
signaling promotes pathologic chronic itch and that interrupting 
these signals may represent an effective strategy to target itch. To 
test this, they generated the first sensory neuron specific cytokine 
receptor knockout mice (NaV1.8-Cre:IL-4Rfl/fl) and showed that 
IL-4−/− nociceptors mice are protected from AD-induced skin 
inflammation, displaying a distinct skin transcriptional profile 
characterized by reduced infiltration of Th2 and basophils 
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numbers. In a distinct skin inflammatory model, toxin-induced 
ablation of Nav1.8+ nociceptors reverse imiquimod (via TLR7)-
mediated psoriasis-like inflammation (46) while cutaneous 
denervation in psoriatic mice reduces the number of immune 
cells in lesions (72).
iNFLAMMATORY ReFLeX
While the sensory neuron axon reflex contributes to local tissue 
immune cell recruitment and activation, immune homeostasis 
is also under autonomic control, in the form of an “anti-inflam-
matory reflex.” This systemic circuit starts when innate immune 
stimuli activate peripheral vagal afferents and terminates with 
efferent parasympathetic neurons inhibiting cytokine produc-
tion by splenic macrophages, attenuating inflammation (32, 73). 
In the efferent arc, action potentials travel down the vagus in 
preganglionic motor fibers to the celiac ganglion to activate post-
ganglionic adrenergic neurons that innervate the spleen. These 
neurons release norepinephrine, activating a special population 
of T cells that make acetylcholine (74). Acetylcholine binds to 
the α7nACHR expressed by splenic macrophages and inhibits 
their production of TNF-α (75). Harnessing the inflammatory 
reflex using bioelectronic devices (76), such as non-invasive 
vagal nerve stimulation, can help decrease the chronic inflam-
mation found in rheumatoid arthritis patients (77) and mice 
with experimental inflammatory bowel disease (78). Similarly, 
non-invasive vagal nerve stimulation showed improved lung 
function in a small patient cohort by reducing exacerbations of 
bronchoconstriction (79).
AiRwAY iMMUNiTY: A MODeL SYSTeM 
FOR DeLiNeATiNG NeURO-iMMUNe 
iNTeRACTiONS
While systemic inflammation detected by the vagus perhaps leads 
to an anti-inflammatory reflex, the local picture in the tissue is 
different. The vagus nerve innervates virtually all visceral organs, 
and nearly 20% of afferents neurons terminate within the airways 
(80). Although some lumbar neurons innervate the lung epithe-
lium (81, 82), it is estimated that up to 95% of the innervation is 
of vagal origin (83). The vagal sensory neurons innervating the 
respiratory tract are situated in two distinct ganglia, the nodose 
and jugular ganglion which have distinct phenotypes, embryonic 
origins (neural crest vs placode), anatomical projections to the 
respiratory tract, and brain stem, and are likely to serve distinct 
functions. Most of the nodose ganglion afferent fiber express 
markers of nociceptors, including TRP channels (TRPA1, 
TRPV1, and TRPM8) (84), voltage-gated sodium channels 
(NaV1.7, NaV1.8, and NaV1.9), voltage-gated calcium channels 
(CaV2.2) and mechanosensitive channels (Piezo2) (85). While 
these nociceptors mostly serve a defensive role by detecting 
chemical, mechanical, or thermal threats and initiate essential, 
protective airway reflexes such as cough and bronchoconstric-
tion (86), they may also directly respond to decreases in lung 
compliance leading to subconscious sighs or deep inspirations 
(87). Physiologically, airway nociceptors can evoke both cough 
and neurogenic inflammation, the latter being a consequence of 
the axon reflex discussed above (8, 88, 89).
There are several indications that nerves and immune cells 
talk to each other in the lung, and this communication may 
have special relevance in asthma. Asthma is a chronic inflamma-
tory disease of the airway which is caused by a combination of 
environmental (90) and genetic factors (91). Asthmatic patients 
have a denser network of sensory fibers around airways (92, 93) 
and a reduced threshold for neuronal activation in response to 
airborne irritants (94) as well as increased neuropeptide levels 
in these neurons (95). Collectively these features indicate exces-
sive activity of peptidergic sensory fibers during asthma (96). 
T  cells clustering with nerve-contacting DCs proliferate only 
in the airways of mice with allergic inflammation but not in the 
airways of negative controls (97). Eosinophils also appear to 
cluster around airway nerves in patients with fatal asthma and in 
antigen-challenged animals (98), while eosinophil-derived basic 
proteins enhance activation of rat pulmonary sensory neurons 
(99). C-fiber denervation in rats decreases the numbers of DCs 
in the lung and pulmonary lymphatic immune cell influx (100) 
while lung nociceptor stimulation with capsaicin increases both 
neuropeptide release and immune cell infiltration (8, 100–104). 
Similarly, stimulation of sensory neurons with capsaicin in 
subjects with active allergic rhinitis produces a reproducible and 
dose-dependent leukocyte influx (105), while capsaicin desen-
sitization reduces rhinitis allergen-challenge symptoms (106). 
SP, CGRP, VIP, and secretin all promote eosinophil chemotaxis 
in vitro (107). SP and neurokinin A are expressed by lung nocic-
eptor afferents and released following a broad range of different 
stimuli, including allergens, ozone, or inflammatory mediators. 
Neurokinin 1 receptor blockade decreases mononuclear cells and 
neutrophils (108) and eosinophils in alveoli (109) while SP (110) 
or capsaicin (111) drive eosinophil influx, which suggests that 
sensory neuron-release of the neuropeptides may drive eosino-
philia in both allergic asthma and hypersensitivity pneumonitis 
(112). Using single-cell RNA-seq, it was recently found that the 
Neuromedin U receptor 1 (NMUR1) was preferentially expressed 
by ILC2s after alarmin (IL-25) stimulation. Neuromedin U 
(NMU), the ligand of NMUR1, activated ILC2s in  vitro, and 
in vivo co-administration of NMU with IL-25 strongly amplified 
allergic inflammation. Despite the limited lung innervation, 
NMU was found only expressed in lung afferent DRG neurons, 
not nodose vagal neurons, and the loss of NMU–NMUR1 signal-
ing reduced ILC2 function, altered transcriptional programs fol-
lowing allergen-challenge in vivo and prevented the development 
of allergic airway inflammation (113).
Neurons also play a regulatory role in allergic airway inflam-
mation; CD11c+ airway mucosal DCs are in close contact with 
CGRP+ nociceptors in both rodents and human subjects (63, 114). 
CGRP has also been shown to have a Th2-skewing preference (68, 
115) CGRP-exposed DCs seemed to enhance Th2 type immunity 
(115, 116), increasing IL-4 production while decreasing Th1-
associated cytokines IFN-γ and IL-2 (117–119). However, despite 
these reports, the majority of publications on the role of CGRP on 
DC in the lung suggest a predominant anti-inflammatory rather 
than pro-inflammatory effect. Pretreating DCs reduces the activa-
tion and proliferation of antigen-specific T cells and increases the 
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numbers of T regulatory cells (120). CGRP specifically inhibits 
the maturation of DCs in vitro while adoptive transfer of CGRP-
pretreated DCs diminishes allergic airway inflammation in vivo, 
with reduced eosinophils and increased IL-10 in bronchoalveolar 
lavage fluid (BALF) (65).
As reviewed by Mazzone and Undem (80), the plastic nature 
of vagal sensory neurons in the lung typically leads to highly 
context-dependent responses to inflammatory cues. For example, 
(1) allergen-sensitization produces a vigorous increase in the 
number and amplitude of IL-5-medicated calcium responses 
in vagal nociceptors (8); (2) allergen-challenge triggers action 
potential firing in nodose ganglion nociceptors of allergen-
sensitized guinea pig (80) and mice (121), but not in naïve 
animals; (3) allergen-challenge increased the excitability of A 
delta fibers to mechanical activation (122); (4) 24  h following 
an allergen-challenge, up to 25% of large neurofilament-positive 
nodose ganglion neurons innervating the respiratory tract start 
expressing SP and CGRP (93); (5) 24 h following BDNF exposure, 
nodose ganglion neurons innervating the trachea start express 
functional TRPV1 (123); and (6) allergen-challenge lowers the 
action potential firing threshold and increases the spiking rate of 
nucleus of the solitary tract (NTS) neurons, which is the brain-
stem structure innervated by the vagus nerve that mediates many 
of its sensory functions (80). The context-dependent plasticity of 
nociceptors may be acute, as in the case of enhanced coughing 
following capsaicin or bradykinin delivery to the airways (124), 
or may be long-lasting due to changes in the CNS similar to the 
central sensitization following peripheral injury (125).
SeNSORY NeURON ROLe iN Th1 vs Th2 
iMMUNiTY iN THe LUNG
Given the data indicating substantial plasticity and a diverse set of 
roles for sensory neurons in different inflammatory disorders in 
the lung, we decided to investigate the specific role of nociceptors 
in regulating immune cells in ovalbumin (OVA) and house dust 
mite models of allergic airway inflammation (8). In this study, 
we demonstrated an involvement of vagal sensory neurons in the 
murine Th2-skewed OVA model of allergic inflammation using 
aluminum hydroxide (AlOH) as adjuvant. This operated through 
a VIP–VPAC2 axis: nociceptors by releasing VIP drive VPAC2 
expressing CD4+ and ILC2 cells to release IL-5 which, in turn, 
activates sensory neurons in the lung to release more VIP (8). 
Similar results were obtained for the house dust mite model. This 
indicates that nociceptors amplify adaptive immune responses in 
the lung in response to allergen exposure in sensitized animals, at 
least in the setting of Th2 immune responses. We then found that 
temporary local pharmacological silencing of the nociceptors is 
sufficient to interrupt this pro-inflammatory signaling loop, a 
non-immune therapeutic strategy that has immunosuppresive 
action. This strategy aims to temporarily silence afferents in the 
adult lung using large pore ion channels as a drug entry port for 
charged sodium channel blockers to produce targeted action 
potential blockade only in activated nociceptors (126, 127). 
These charged molecules have no action extracellularly but block 
sodium channels when they get into the cell. Because of their 
cationic charge, they cannot permeate through the membrane but 
are small enough to enter cells through inflammation-activated 
TRPV1 and TRPA1 ion channels (126, 128).
Specifically, a single treatment with QX-314 (100 µM or 0.003%, 
nebulized for 20 min at 20 psi, day 18), a quaternary derivative of 
lidocaine, to OVA sensitized (day 0 and 7) and challenged (days 
14, 15, 16, and 17) mice substantially reduces lung immune cell 
infiltration (day 21), with decreases in BALF numbers of leuko-
cytes, eosinophils, macrophages, and lymphocytes (8). Building 
on these findings, we used this strategy to assess the influence 
of nociceptor ablation or silencing on the activity of primary 
immune drivers (ILC2 and DCs) of type 2 inflammation. Here, 
we generate new data showing that QX-314 abolishes the rise in 
lung ILC2 cells, ILC2-derived IL-5, as well as BALF inflammatory 
DC cells (Figures 1A–C). Thus, pharmacologic silencing of noci-
ceptors results in decreased activation of ILC2s and Th2 effector 
cytokine production. The above protocol, sensitizing 8-week-
old male BALB/c mice with OVA and aluminum hydroxide as 
adjuvant, produces a Th2-skewed inflammation (129). When 
mice are sensitized with a complete Freund adjuvant (CFA) and 
OVA, this produces non-eosinophilic Th1-skewed asthma (129). 
Remarkably in these mice, QX-314 treatment (100 µM or 0.003%, 
nebulized for 20 min at 20 psi, day 18) fails to impact the levels of 
CD3+ cells (Figure 1D), macrophages (Figure 1E), and neutro-
phils (Figure 1F). These data show that the contribution of vagal 
nociceptors on allergic inflammation is context-dependent with 
respect to the type of initial immune priming, with substantial 
neuronal involvement in type 2 models of allergic airway inflam-
mation but not in a type 1 model.
wHY wOULD NOCiCePTORS 
PARTiCiPATe iN Th2 BUT NOT  
Th1 iMMUNiTY?
Type 2 immune responses evolved to eliminate parasites and 
other organisms that cannot be taken care of by cell-mediated 
immunity. The best early defense against parasites are direct 
behavioral reactions elicited acutely by the parasite as a sensory-
motor reflex arc; for example, the sensation of itch as a parasite 
invades the skin leads to a reflex action of scratching. Worms 
in the gut initiate peristalsis and, in the lung, parasites lead to 
cough and enhanced mucus production. We postulate that the 
neuronal response became associated with the type 2 immune 
response elicited by parasites in order to enable a coordinated 
defense response: release of histamine and IL-4 (which sensitize 
nociceptors), production of mucus (also due to joint neuro-
immune effort), and of IgE antibodies. Thus, the linkage between 
sensation (airway irritancy) and behavior (cough) expanded to 
become a link between sensory neuron activation and immunity. 
Supporting this idea, allergens and other type 2 stimuli directly 
activate sensory neurons in tissues where parasites might be 
particularly active (lung mucosa, for example). An example: as 
discussed above, acetylcholine-producing neurons of the enteric 
nervous system are found in close proximity to ILC2 cells. In 
addition to their role in allergic inflammation, it was also recently 
reported that these neurons can directly sense worm products 
FiGURe 1 | Nociceptor activation promotes Th2 but not Th1 airway inflammation. In the aluminum hydroxide (AlOH)/ovalbumin (OVA) sensitized mice (A–C),  
a standard model of airway Th2-driven inflammation, OVA-challenge do not significantly increase the numbers of ILC2 cells (A) in the lung but did enhance their 
production of IL-5 (B) as well as the numbers of inflammatory dendritic cells (DCs) in bronchoalveolar lavage fluid (BALF) (C). Silencing lung sensory neurons with 
aerosolized QX-314 (0.003%, 20 min nebulization, 20 psi) decreased these Th2 immune cell responses. By contrast, silencing nociceptors in a Th1-driven lung 
inflammation model [complete Freund’s adjuvant (CFA)]/OVA sensitized mice; (D–F), had no impact on the OVA-challenge induced increases in BALF CD3+ (D), 
eosinophils (e), and macrophages (F). Mean ± SEM; Two-tailed unpaired Welsh’s t-test (n = 5–12 animals/group; 1–2 cohorts).
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(N. brasiliensis excretory/secretory products) and alarmins (IL-
33), and, in turn, release neuromedin U to activate ILC2 cells. 
Thus, ILC2-autonomous ablation of Nmur1, the NMU receptor, 
impaired type 2 responses and control of worm infection. These 
data support a role for mucosal neurons to provide immediate 
tissue protection against worm products and alarmins and mount 
type 2 inflammatory responses (130). Future experiments will 
determine the extent of this linkage, and whether it holds true 
for other organs.
CONCLUDiNG ReMARKS
As summarized in Figure  2, the influence of nociceptors on 
inflammation depends on the context (allergen sensitized or not) 
(80), the subtype of neuron activated, the subtype of immune 
cell that will respond to neuropeptide release, the location of the 
interaction (mucosal, epithelial, and endothelial), the timing of 
the interaction (acute vs chronic), and as our data suggests, the 
type of immune response (type 1 vs type 2). How, specifically, 
might nociceptors play different roles in different locations and in 
different types of immunity? One answer might lie in differences 
in expression of peptides and receptors. Nociceptors express 
receptors for 20 cytokines, 8 chemokines, and 6 immunoglobulins. 
They also express pattern recognition receptors, including two 
formyl peptide receptors, 11 toll-like receptors and 13 nucleotide-
binding oligomerization domain-like receptors (131). Another 
example of the diverse functions of nociceptors is their expres-
sion of the immune checkpoint receptor PD-1 and their response 
to its cognate ligand (PD-L1) (132). PD-1 activation induces 
phosphorylation of the tyrosine phosphatase SHP-1, which 
inhibits sodium channels and decreases nociceptor sensitivity 
(132). Nociceptors also express in excess of 80 neuropeptides, 
each specific for receptors present at variable levels on various 
immune cells, creating the capacity to produce multiple different 
FiGURe 2 | Context-dependent neuro-immune interactions; nociceptors participate in Th2 but not Th1 type inflammation depending on the tissue type. Left panel. 
In type 2 inflammation, allergens or parasites are sensed by epithelial and dendritic cells (DCs). Epithelial cells may secrete mediators such as thymic stromal 
lymphopoietin (TSLP) which sensitize nociceptors. Nociceptors release neuropeptides including VIP which act on DCs and Th2 cells and contribute to their 
activation. Th2 cells secrete cytokines (IL-4 and IL-5) that both drive type 2 inflammation and act on nociceptors forming an inflammatory loop. While such 
inflammation perhaps aids in parasite clearance by promoting coughing and mucus secretion, if amplified and prolonged, this bidirectional communication 
contributes to the pathology of allergic inflammation. Right panel. The case is different in our model of Th1 type inflammation where the neuropeptides secreted by 
nociceptors do not activate immune cells and may even actively inhibit type 1 immunity. In this situation, nociceptors may sense pathogen-associated molecules 
and produce neuropeptides that limit DCs activation and downstream Th1 responses.
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outcomes. The basal expression levels of both the neuropeptides 
and their cognate receptors vary in different inflammatory 
contexts and anatomical origins (lumbar vs vagal afferent) (131). 
Vagal nociceptors, for example, express higher level of Chrna5 
(6.4-fold), TRPA1 (1.6-fold), VIP (16.2-fold), and IL-22R (9.2-
fold) than somatic dorsal root ganglion neurons, while the latter 
express higher levels of KV7.5 (24.3-fold), TRPM8 (4.0-fold), 
CGRP (3.2-fold), and IL-31R (10.3-fold) (131).
Keeping in mind that immune cells themselves can release 
neurotransmitters such as dopamine by germinal center TFH cells 
(133), we now need to examine in detail the broad repertoire by 
means of which sensory neurons and immune cells communicate 
with each other locally in damaged or infected tissue and explore 
where and how this contributes to disease. The development of 
new tools to monitor the in  vivo activity of specific neuronal 
populations (by GCaMP6 and two-photon microscopy) and to 
stimulate (through optogenetics, DREADD), or block/ablate 
these neurons genetically (tetanus toxin, diphtheria toxin) or 
pharmacologically (QX-314), will help further dissect out the 
local sensory neuron–immune axis, especially when paired with 
single immune cell and neuron transcript profiling. Exploring 
the immune and nervous system contributions to inflammatory 
diseases will, we are confident, reveal novel therapeutic targets.
eXPeRiMeNTAL PROCeDUReS
All procedures were approved by the Institutional Animal Care 
and Use Committees of Boston Children’s Hospital. Mice were 
housed in standard environmental conditions (12  h light/dark 
cycle; 23°C; food and water ad libitum) at facilities accredited by 
the Association for Assessment and Accreditation of Laboratory 
Animal Care. Allergic airway inflammation was studied in 
8-week-old male BALB/c (stock number: 000651) mice using 
the classic OVA model (134) of asthma. On day 0 and 7, mice 
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were sensitized by a 200 µl i.p. injections of a solution containing 
1 mg/ml OVA (Sigma-Aldrich) and 5 mg/ml aluminum hydrox-
ide (AlOH; Sigma-Aldrich, Boston, MA, USA). On days 14–17 
(10:00 a.m.) mice were exposed to 6% OVA aerosol for 20 min. 
We also investigated impact of sensory neuron silencing in a 
TH1-skewed model of allergic airway inflammation (129) follow-
ing s.c. sensitization with OVA (1 mg/ml) in a 200 µl emulsion 
of sterile PBS and 50% CFA on day 0 and with 50% incomplete 
Freund adjuvant (IFA) on day 7.
Drugs
QX-314 (126) (Tocris) was diluted in sterile PBS to a 0.003% 
concentration (100 µmol) and mice were nebulized for 20 min at 
20 psi on day 18 (8).
Bronchoalveolar Lavage Fluid
On day 21, a 20 G sterile catheter was inserted longitudinally into 
the trachea of deeply urethane-anesthetized mice (1.5 g/kg i.p.). 
Two milliliters of ice-cold PBS containing protease inhibitors 
were injected into the lung, harvested, stored on ice, centrifuged, 
cells isolated, and resuspended in sterile PBS (2, 58).
FACS
Single cells are isolated in FACS buffer (PBS, 2% FCS, EDTA), 
blocked (αCD16/CD32, 0.5  mg/ml, 10  min), and stained with 
specific monoclonal antibodies. Using a tiered gating strategy, 
cells are identified using light scatter parameters (FSC by SSC) 
and doublets are excluded. Cell populations are defined as fol-
lows: alveolar macrophages (sygF+CD11b-CD11c+CD64+), DCs 
(CD11c+CD103+CD24+FcεR1+), neutrophils (CD11b+Ly6g+), 
leukocytes (CD45+CD3+), and ILC2 (Lin-Thy1+ST2+CD25Hi) 
(2, 58, 135, 136).
Cell Count
Total BAL cell counts were performed using a standard hemocy-
tometer, with absolute cell numbers calculated as total BAL cell 
number multiplied by the percentage of cell subpopulation as 
determined by FACS (134). Data are presented as fold change in 
comparison to control mice.
intracellular Cytokine Staining
Cells were stimulated with PMA/Ionomycin in the presence of 
GolgiPlug (BD Biosciences) for 4 h and then fixed and stained 
using the BD Cytofix/Cytoperm kit following manufacturer’s 
instructions (BD Biosciences) (8).
STATiSTiCS
Data expressed as mean ± SEM from 5 to 12 mice. Statistical sig-
nificance determined by two-tail unpaired Welsh’s t-test. p-values 
less than 0.05 were considered significant. Numbers of animals 
are indicated on the figure.
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